与标准治疗相比, 新的狼药物DZP可减少50%的疾病活力和严重爆发. New lupus drug DZP cuts disease activity and severe flares by 50% compared to standard treatments.
一项新的研究表明,中度至严重程度狼疮的一种药物 -- -- dapirolizumab Pegol(DZP) -- -- 与标准治疗相比,显著减少了50%的疾病活动和严重耀斑。 A new study shows that dapirolizumab pegol (DZP), a drug for moderate-to-severe lupus, significantly reduced disease activity and severe flares by 50% compared to standard treatments. 这种治疗还使病人能够减少类固醇的使用,而类固醇的使用对防治这一疾病至关重要。 The treatment also allowed patients to reduce steroid use, which is crucial for managing the disease. 该药物实现了首要目标,在改善疾病活动方面,答复率提高了14.6%,表明有可能取得更好的结果,特别是对妇女而言,她们受狼疮的影响更大。 The drug met its primary goal with a 14.6% higher response rate in improving disease activity, indicating potential for better outcomes, especially for women, who are more affected by lupus.